Guardant Health (GH)
(Delayed Data from NSDQ)
$21.40 USD
+0.79 (3.83%)
Updated Oct 11, 2024 04:00 PM ET
After-Market: $21.38 -0.02 (-0.09%) 7:58 PM ET
3-Hold of 5 3
F Value D Growth B Momentum D VGM
We use cookies to understand how you use our site and to improve your experience. This includes personalizing content and advertising. To learn more, click here. By continuing to use our site, you accept our use of cookies, revised Privacy Policy and Terms of Service.
You are being directed to ZacksTrade, a division of LBMZ Securities and licensed broker-dealer. ZacksTrade and Zacks.com are separate companies. The web link between the two companies is not a solicitation or offer to invest in a particular security or type of security. ZacksTrade does not endorse or adopt any particular investment strategy, any analyst opinion/rating/report or any approach to evaluating individual securities.
If you wish to go to ZacksTrade, click OK. If you do not, click Cancel.
$21.40 USD
+0.79 (3.83%)
Updated Oct 11, 2024 04:00 PM ET
After-Market: $21.38 -0.02 (-0.09%) 7:58 PM ET
3-Hold of 5 3
F Value D Growth B Momentum D VGM
Zacks News
Liquidia Technologies (LQDA) Soars 14.1%: Is Further Upside Left in the Stock?
by Zacks Equity Research
Liquidia Technologies (LQDA) witnessed a jump in share price last session on above-average trading volume. The latest trend in earnings estimate revisions for the stock doesn't suggest further strength down the road.
Guardant Health (GH) Recently Broke Out Above the 20-Day Moving Average
by Zacks Equity Research
Is it a good or bad thing when a stock surpasses resistance at the 20-day simple moving average?
Guardant Health (GH) Q2 Earnings: How Key Metrics Compare to Wall Street Estimates
by Zacks Equity Research
While the top- and bottom-line numbers for Guardant Health (GH) give a sense of how the business performed in the quarter ended June 2024, it could be worth looking at how some of its key metrics compare to Wall Street estimates and year-ago values.
Guardant Health (GH) Reports Q2 Loss, Tops Revenue Estimates
by Zacks Equity Research
Guardant Health (GH) delivered earnings and revenue surprises of 15.79% and 9.45%, respectively, for the quarter ended June 2024. Do the numbers hold clues to what lies ahead for the stock?
What Analyst Projections for Key Metrics Reveal About Guardant Health (GH) Q2 Earnings
by Zacks Equity Research
Beyond analysts' top -and-bottom-line estimates for Guardant Health (GH), evaluate projections for some of its key metrics to gain a better insight into how the business might have performed for the quarter ended June 2024.
Merus N.V. (MRUS) Reports Q2 Loss, Lags Revenue Estimates
by Zacks Equity Research
Merus (MRUS) delivered earnings and revenue surprises of -6.58% and 23.94%, respectively, for the quarter ended June 2024. Do the numbers hold clues to what lies ahead for the stock?
Guardant Health (GH) Moves 6.9% Higher: Will This Strength Last?
by Zacks Equity Research
Guardant Health (GH) witnessed a jump in share price last session on above-average trading volume. The latest trend in earnings estimate revisions for the stock doesn't suggest further strength down the road.
Guardant Health (GH) Just Overtook the 20-Day Moving Average
by Zacks Equity Research
Should investors be excited or worried when a stock crosses above the 20-day simple moving average?
Guardant Health (GH) Now Trades Above Golden Cross: Time to Buy?
by Zacks Equity Research
Is it a good or bad thing when a stock experiences a golden cross technical event?
Guardant Health (GH) Recently Broke Out Above the 200-Day Moving Average
by Zacks Equity Research
When a stock breaks out above the 200-day simple moving average, good things could be on the horizon. How should investors react?
Stock Market News for May 13, 2024
by Zacks Equity Research
U.S. stocks closed mixed on Friday as investors awaited the April Consumer Price Index report, which is influential in shaping the Federal Reserve's interest rate policies, alongside assessing quarterly earnings.
Compared to Estimates, Guardant Health (GH) Q1 Earnings: A Look at Key Metrics
by Zacks Equity Research
Although the revenue and EPS for Guardant Health (GH) give a sense of how its business performed in the quarter ended March 2024, it might be worth considering how some key metrics compare with Wall Street estimates and the year-ago numbers.
Guardant Health (GH) Reports Q1 Loss, Tops Revenue Estimates
by Zacks Equity Research
Guardant Health (GH) delivered earnings and revenue surprises of 36.11% and 11.94%, respectively, for the quarter ended March 2024. Do the numbers hold clues to what lies ahead for the stock?
MannKind (MNKD) Beats Q1 Earnings and Revenue Estimates
by Zacks Equity Research
MannKind (MNKD) delivered earnings and revenue surprises of 150% and 13.76%, respectively, for the quarter ended March 2024. Do the numbers hold clues to what lies ahead for the stock?
Guardant (GH) Gears Up for Q1 Earnings: Here's What to Expect
by Zacks Equity Research
Investors' focus will likely be on revenues generated by Guardant Health (GH) from its precision oncology testing business.
Curious about Guardant Health (GH) Q1 Performance? Explore Wall Street Estimates for Key Metrics
by Zacks Equity Research
Besides Wall Street's top -and-bottom-line estimates for Guardant Health (GH), review projections for some of its key metrics to gain a deeper understanding of how the company might have fared during the quarter ended March 2024.
These 2 Medical Stocks Could Beat Earnings: Why They Should Be on Your Radar
by Zacks Equity Research
Investors looking for ways to find stocks that are set to beat quarterly earnings estimates should check out the Zacks Earnings ESP.
Guardant Health (GH) Reports Q4 Earnings: What Key Metrics Have to Say
by Zacks Equity Research
The headline numbers for Guardant Health (GH) give insight into how the company performed in the quarter ended December 2023, but it may be worthwhile to compare some of its key metrics to Wall Street estimates and the year-ago actuals.
Guardant Health (GH) Reports Q4 Loss, Tops Revenue Estimates
by Zacks Equity Research
Guardant Health (GH) delivered earnings and revenue surprises of -69.89% and 2.20%, respectively, for the quarter ended December 2023. Do the numbers hold clues to what lies ahead for the stock?
Wall Street Analysts Think Guardant Health (GH) Could Surge 109.89%: Read This Before Placing a Bet
by Zacks Equity Research
The average of price targets set by Wall Street analysts indicates a potential upside of 109.9% in Guardant Health (GH). While the effectiveness of this highly sought-after metric is questionable, the positive trend in earnings estimate revisions might translate into an upside in the stock.
NeoGenomics (NEO) Q4 Earnings and Revenues Beat Estimates
by Zacks Equity Research
NeoGenomics (NEO) delivered earnings and revenue surprises of 400% and 1.73%, respectively, for the quarter ended December 2023. Do the numbers hold clues to what lies ahead for the stock?
Guardant Health (GH) Expected to Beat Earnings Estimates: Can the Stock Move Higher?
by Zacks Equity Research
Guardant Health (GH) possesses the right combination of the two key ingredients for a likely earnings beat in its upcoming report. Get prepared with the key expectations.
Down -12.91% in 4 Weeks, Here's Why Guardant Health (GH) Looks Ripe for a Turnaround
by Zacks Equity Research
Guardant Health (GH) is technically in oversold territory now, so the heavy selling pressure might have exhausted. This along with strong agreement among Wall Street analysts in raising earnings estimates could lead to a trend reversal for the stock.
Guardant Health (GH) Loses -13.59% in 4 Weeks, Here's Why a Trend Reversal May be Around the Corner
by Zacks Equity Research
Guardant Health (GH) has become technically an oversold stock now, which implies exhaustion of the heavy selling pressure on it. This, combined with strong agreement among Wall Street analysts in revising earnings estimates higher, indicates a potential trend reversal for the stock in the near term.
Bull of the Day: NeoGenomics (NEO)
by Kevin Cook
Small-cap leader in oncology diagnostics is on sale after patent litigation takes a bite